Hematology

Latest News

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers. | Image credit: wladimir1804 - AdobeStock_408414612
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

June 11th 2025

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy
April 4th 2020

FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy

Maggie L. Shaw
The FDA has announced a relaxing of its restrictions on gay men being allowed to donate blood, in light of the coronavirus disease 2019 pandemic. Instead of 1 year, if a male has had sex with another male, he need only wait 3 months to donate blood.
Carfilzomib Improves Prognosis in Patients With High-Risk Multiple Myeloma, Study Finds
March 29th 2020

Carfilzomib Improves Prognosis in Patients With High-Risk Multiple Myeloma, Study Finds

Jared Kaltwasser
Patients with high-risk multiple myeloma tend to have significantly worse prognoses compared to those in the standard-risk category. A new study offers a potential solution.
Site Logo
March 23rd 2020

Why Donate Blood During the Coronavirus Crisis? Because I Can

Maggie L. Shaw
I am type O negative. There are only 7% of us in the United States. My blood is red gold, if you will. I am a universal donor, which means that my blood can go to anyone.
Study Examines Fixed-Duration Therapy in Patients With MM Ineligible for Transplants
March 22nd 2020

Study Examines Fixed-Duration Therapy in Patients With MM Ineligible for Transplants

Jared Kaltwasser
Newly diagnosed patients with multiple myeloma (MM) who are transplant-ineligible sometimes plan fixed-duration therapy to improve their quality of life. A new study examines the impact of that approach.
COVID-19 and Cancer: Practices Seek to Protect Patients, Providers From Growing Pandemic
March 21st 2020

COVID-19 and Cancer: Practices Seek to Protect Patients, Providers From Growing Pandemic

Allison Inserro
Some patients with cancer are more vulnerable than others, said Jeffrey Patton, MD, acting chief executive officer and president of physician services of OneOncology, as well as chief executive office of Tennessee Oncology, which is down to its last 14-day supply of personal protective equipment.
Hydroxycarbamide Therapy Shown to Improve Memory, IQ of Adolescents With Sickle Cell Disease
March 17th 2020

Hydroxycarbamide Therapy Shown to Improve Memory, IQ of Adolescents With Sickle Cell Disease

Matthew Gavidia
In adolescent patients with sickle cell disease, hydroxycarbamide therapy was associated with improvements in neurocognition variables such as working memory, verbal memory, and nonverbal IQ, according to study findings.
Dr Elisabet Manasanch Discusses Current Standards of Treatment for Smoldering Multiple Myeloma
March 16th 2020

Dr Elisabet Manasanch Discusses Current Standards of Treatment for Smoldering Multiple Myeloma

There are studies exhibiting progression within treatment for smoldering multiple myeloma, but nothing has been FDA approved yet, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Dr C. Patrick Carroll Discusses Treating Patients With SCD-Related Pain Who Arrive in the ED
March 12th 2020

Dr C. Patrick Carroll Discusses Treating Patients With SCD-Related Pain Who Arrive in the ED

When patients present to the emergency department (ED) with sickle cell disease (SCD)–related pain, they often have been experiencing that pain for days, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Vitamin D Deficiency Associated With Worse Hospital Outcomes in Pediatric Patients With Sickle Cell Disease
March 11th 2020

Vitamin D Deficiency Associated With Worse Hospital Outcomes in Pediatric Patients With Sickle Cell Disease

Matthew Gavidia
In children and adolescents with sickle cell disease, those who lacked ample vitamin D were hospitalized more often, had longer hospital stays, and made more frequent visits to the emergency department, according to study findings.
What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab
March 9th 2020

What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab

AJMC Staff
A year after being only the second person to be cured of HIV, the “London Patient” revealed his identity; BMS announced today that its combination therapy for multiple myeloma—elotuzumab, lenalidomide, and dexamethasone—failed its primary endpoint of progression-free survival in its phase 3 ELOQUENT-1 trial; Biocon and Mylan N.V. announced that the FDA accepted their biologics license application (BLA) for MYL-14020, a proposed biosimilar to bevacizumab (Avastin), for review.
FDA Approves Isatuximab-irfc for Treatment of Relapsed Refractory Multiple Myeloma
March 5th 2020

FDA Approves Isatuximab-irfc for Treatment of Relapsed Refractory Multiple Myeloma

Matthew Gavidia
Isatuximab-irfc, sold as Sarclisa, in combination with pomalidomide and dexamethasone, was approved this week by the FDA for the treatment of adults with relapsed refractory multiple myeloma who have received at least 2 prior therapies.
Dr Adam Olszewski on Research Still Needed on Palliative Care Services in Blood Cancers
March 3rd 2020

Dr Adam Olszewski on Research Still Needed on Palliative Care Services in Blood Cancers

More data is needed to get wider acceptance of the use of palliative care services for patients with blood cancers, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
Higher Microbiota Diversity in Hematologic Cancer Treatment Could Lower Mortality Risk, Study Finds
February 27th 2020

Higher Microbiota Diversity in Hematologic Cancer Treatment Could Lower Mortality Risk, Study Finds

Matthew Gavidia
For patients undergoing allogeneic hematopoietic cell transplantation, higher diversity of intestinal microbiota at the time of neutrophil engraftment was linked with lower mortality, according to study findings published today.
Multiple Myeloma Rates in China Align With Other Asian Countries
February 23rd 2020

Multiple Myeloma Rates in China Align With Other Asian Countries

Jared Kaltwasser
In a major study of a Chinese medical insurance database, investigators found the prevalence and incidence of the disease in China is similar to those of its neighbors, but lower than countries in the West.
Dr C. Patrick Carroll on Biases Impacting African Americans With Sickle Cell Disease and Pain
February 19th 2020

Dr C. Patrick Carroll on Biases Impacting African Americans With Sickle Cell Disease and Pain

Patients with sickle cell disease already face suspicion and biases based on their need for opioids, and African American patients also face additional racial biases, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Imaging CAR T Cells Will Assist Doctors' Treatment Strategies, Says Dr Reona Sakemura
February 18th 2020

Imaging CAR T Cells Will Assist Doctors' Treatment Strategies, Says Dr Reona Sakemura

Predicting T-cell toxicity is a key factor when it comes to successfully using CAR T-cell therapy, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Sickle Cell Trait, Disease Linked With Faster Kidney Function Decline in African American Patients
February 18th 2020

Sickle Cell Trait, Disease Linked With Faster Kidney Function Decline in African American Patients

Matthew Gavidia
Sickle-cell trait (SCT) and disease (SCD) among African American patients were associated with faster kidney function decline, with SCD contributing to a more rapid decline, according to study findings.
Scientists Unveil New Target to Stop Bortezomib Resistance in Patients With Multiple Myeloma
February 16th 2020

Scientists Unveil New Target to Stop Bortezomib Resistance in Patients With Multiple Myeloma

Jared Kaltwasser
Primary and acquired resistance to bortezomib can increase recurrence rates in patients with multiple myeloma. A new strategy could help reduce resistance.
Dr Adam Olszewski: Early Palliative Care Is Important and Beneficial for Patients With Blood Cancers
February 15th 2020

Dr Adam Olszewski: Early Palliative Care Is Important and Beneficial for Patients With Blood Cancers

Evidence is showing that early palliative care can be beneficial for patients with blood cancers, who receive very intense treatments that impact quality of life, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
Early Study of Bendamustine, Carfilzomib Shows Encouraging Results
February 14th 2020

Early Study of Bendamustine, Carfilzomib Shows Encouraging Results

AJMC Staff
Researchers describe results of carfilizomib and bendamustine in a phase 1/2 study.
Daratumumab-Based Combination Regimen Submitted for FDA Approval in Relapsed/Refractory Multiple Myeloma
February 12th 2020

Daratumumab-Based Combination Regimen Submitted for FDA Approval in Relapsed/Refractory Multiple Myeloma

Matthew Gavidia
Based on positive data from the phase 3 CANDOR study presented at the 2019 American Society of Hematology Annual Meeting, Janssen announced yesterday the submission of a supplemental biologics license application to the FDA seeking approval of daratumumab in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
Dr Reona Sakemura Explains Why Certain Cancers Are More Susceptible to CAR T-Cell Therapy
February 11th 2020

Dr Reona Sakemura Explains Why Certain Cancers Are More Susceptible to CAR T-Cell Therapy

Bone marrow derived cancer-associated fibroblasts promote tumor progression which can alter a treatment's course, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Dr C. Patrick Carroll on Barriers to Accessing Nonpharmacologic Treatments to SDC-Related Pain
February 8th 2020

Dr C. Patrick Carroll on Barriers to Accessing Nonpharmacologic Treatments to SDC-Related Pain

There is not a lot of evidence on how well nonpharmacologic treatments work to treat sickle cell disease–related pain, and it can be difficult to get people access to these treatments, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies
February 4th 2020

Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies

Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma
January 31st 2020

Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma

Maggie L. Shaw
Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib, a next-generation PI, treats RRMM as both a monotherapy and in combination; and ixazomib, the first oral PI, treats RRMM in combination. PIs work by preventing the proteasomes in cancerous plasma cells from “recycling” what is essentially garbage protein.
Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell Disease–Related Pain
January 30th 2020

Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell Disease–Related Pain

Patients had never been particularly enthusiastic about using opioids to treat their pain related to sickle cell disease, but they are more cautious now, especially as they are often meet with suspicion of addiction, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease
January 29th 2020

Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease

Managing people with sickle cell disease and complex chronic pain is difficult and requires some trial and error, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia
January 25th 2020

ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia

Matthew Gavidia
The Institute for Clinical and Economic Review (ICER) published a draft evidence report on crizanlizumab (Adakveo), voxelotor (Oxbryta), and L-glutamine (Endari) for sickle cell disease, as well as a draft scoping document on valoctocogene roxaparvovec, an investigational gene therapy, and emicizumab (Helimbra) for hemophilia.
Site Logo
January 22nd 2020

Managing Vaso-Occlusive Crisis in Sickle Cell Disease: A Look at the Clinical and Economic Burden

https://www.pharmacytimes.org/on-demand/managing-vasoocclusive-crisis-in-sickle-cell-disease-a-look-at-the-clinical-and-economic-burden
Site Logo
January 21st 2020

Biosimilars at ASH 2019: Data on Truxima and Competitors for Eculizumab

Kelly Davio
Results for Truxima, recently launched in the United States, and complement inhibitors were presented at the 61st American Society of Hematology Annual Meeting and Exposition.
<1
...
789101112131415
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo